Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
Status:
Withdrawn
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of Cabozantinib in combination with Nivolumab
and Ipilimumab and see what affects that this combination treatment has on those with
recurrent carcinosarcomas.